Equities analysts forecast that Achaogen Inc (NASDAQ:AKAO) will announce $3.86 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Achaogen’s earnings. The lowest sales estimate is $2.23 million and the highest is $6.30 million. Achaogen reported sales of $1.87 million in the same quarter last year, which suggests a positive year over year growth rate of 106.4%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Achaogen will report full year sales of $10.48 million for the current fiscal year, with estimates ranging from $8.93 million to $13.00 million. For the next fiscal year, analysts forecast that the firm will report sales of $29.77 million, with estimates ranging from $11.15 million to $55.50 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that cover Achaogen.
Achaogen (NASDAQ:AKAO) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.08. Achaogen had a negative net margin of 2,045.86% and a negative return on equity of 214.74%. The business had revenue of $2.00 million for the quarter, compared to analyst estimates of $3.80 million.
Achaogen stock traded down $0.04 during midday trading on Friday, reaching $1.39. The company’s stock had a trading volume of 435,400 shares, compared to its average volume of 2,154,837. Achaogen has a fifty-two week low of $1.14 and a fifty-two week high of $15.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.52 and a current ratio of 2.54. The company has a market cap of $62.95 million, a P/E ratio of -0.44 and a beta of 0.83.
In other news, major shareholder Robert W. Duggan bought 743,348 shares of the stock in a transaction dated Tuesday, December 11th. The stock was bought at an average cost of $1.62 per share, with a total value of $1,204,223.76. Following the purchase, the insider now owns 8,880,461 shares of the company’s stock, valued at $14,386,346.82. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Robert W. Duggan bought 22,431 shares of the stock in a transaction dated Friday, December 7th. The stock was purchased at an average cost of $1.40 per share, with a total value of $31,403.40. Following the completion of the purchase, the insider now directly owns 8,443,961 shares in the company, valued at approximately $11,821,545.40. The disclosure for this purchase can be found here. Insiders acquired a total of 1,008,362 shares of company stock valued at $1,677,078 in the last quarter. Corporate insiders own 7.80% of the company’s stock.
Several large investors have recently bought and sold shares of AKAO. JPMorgan Chase & Co. lifted its holdings in Achaogen by 2,745.0% during the third quarter. JPMorgan Chase & Co. now owns 294,768 shares of the biopharmaceutical company’s stock worth $1,176,000 after acquiring an additional 284,407 shares in the last quarter. AXA raised its stake in shares of Achaogen by 31.4% in the 3rd quarter. AXA now owns 903,425 shares of the biopharmaceutical company’s stock valued at $3,605,000 after purchasing an additional 215,989 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Achaogen in the third quarter valued at about $823,000. Bank of America Corp DE increased its position in shares of Achaogen by 274.7% in the second quarter. Bank of America Corp DE now owns 198,204 shares of the biopharmaceutical company’s stock valued at $1,717,000 after acquiring an additional 145,305 shares during the last quarter. Finally, Granahan Investment Management Inc. MA acquired a new stake in shares of Achaogen in the second quarter valued at about $1,220,000. Institutional investors and hedge funds own 45.59% of the company’s stock.
Achaogen, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae.
Recommended Story: What is the Ex-Dividend Date in Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.